News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA Grants Fast Track Designation for Cubist Pharmaceuticals, Inc. (CBST)’s Late-Stage Antibiotic Candidate


5/7/2013 11:12:04 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that the U.S. Food and Drug Administration (FDA) has granted the Company’s late-stage antibiotic candidate ceftolozane/tazobactam (CXA-201) Fast Track status in the previously granted Qualified Infectious Disease Product (QIDP) indications, Hospital-Acquired Bacterial Pneumonia (HABP)/Ventilator-Associated Bacterial Pneumonia (VABP) and Complicated Urinary Tract Infections (cUTI). The FDA granted Fast Track status for ceftolozane/tazobactam in Complicated Intra-Abdominal Infections (cIAI) in February 2013.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES